Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects

In recent years, the vital role of genetic factors in human diseases have been widely recognized by scholars with the deepening of life science research, accompanied by the rapid development of gene-editing technology. In early years, scientists used homologous recombination technology to establish...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Genmao Cao, Xuezhen Xuan, Ruijing Zhang, Jie Hu, Honglin Dong
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	gene therapy cardiovascular disease ethical concerns delivering system gene-editing technology Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/23c93cea97e54a12a90c737552338062
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23c93cea97e54a12a90c737552338062
record_format	dspace
spelling	oai:doaj.org-article:23c93cea97e54a12a90c7375523380622021-11-05T10:31:47ZGene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects2297-055X10.3389/fcvm.2021.760140https://doaj.org/article/23c93cea97e54a12a90c7375523380622021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.760140/fullhttps://doaj.org/toc/2297-055XIn recent years, the vital role of genetic factors in human diseases have been widely recognized by scholars with the deepening of life science research, accompanied by the rapid development of gene-editing technology. In early years, scientists used homologous recombination technology to establish gene knock-out and gene knock-in animal models, and then appeared the second-generation gene-editing technology zinc-finger nucleases (ZFNs) and transcription activator–like effector nucleases (TALENs) that relied on nucleic acid binding proteins and endonucleases and the third-generation gene-editing technology that functioned through protein–nucleic acids complexes—CRISPR/Cas9 system. This holds another promise for refractory diseases and genetic diseases. Cardiovascular disease (CVD) has always been the focus of clinical and basic research because of its high incidence and high disability rate, which seriously affects the long-term survival and quality of life of patients. Because some inherited cardiovascular diseases do not respond well to drug and surgical treatment, researchers are trying to use rapidly developing genetic techniques to develop initial attempts. However, significant obstacles to clinical application of gene therapy still exists, such as insufficient understanding of the nature of cardiovascular disease, limitations of genetic technology, or ethical concerns. This review mainly introduces the types and mechanisms of gene-editing techniques, ethical concerns of gene therapy, the application of gene therapy in atherosclerosis and inheritable cardiovascular diseases, in-stent restenosis, and delivering systems.Genmao CaoXuezhen XuanRuijing ZhangJie HuHonglin DongFrontiers Media S.A.articlegene therapycardiovascular diseaseethical concernsdelivering systemgene-editing technologyDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gene therapy cardiovascular disease ethical concerns delivering system gene-editing technology Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	gene therapy cardiovascular disease ethical concerns delivering system gene-editing technology Diseases of the circulatory (Cardiovascular) system RC666-701 Genmao Cao Xuezhen Xuan Ruijing Zhang Jie Hu Honglin Dong Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
description	In recent years, the vital role of genetic factors in human diseases have been widely recognized by scholars with the deepening of life science research, accompanied by the rapid development of gene-editing technology. In early years, scientists used homologous recombination technology to establish gene knock-out and gene knock-in animal models, and then appeared the second-generation gene-editing technology zinc-finger nucleases (ZFNs) and transcription activator–like effector nucleases (TALENs) that relied on nucleic acid binding proteins and endonucleases and the third-generation gene-editing technology that functioned through protein–nucleic acids complexes—CRISPR/Cas9 system. This holds another promise for refractory diseases and genetic diseases. Cardiovascular disease (CVD) has always been the focus of clinical and basic research because of its high incidence and high disability rate, which seriously affects the long-term survival and quality of life of patients. Because some inherited cardiovascular diseases do not respond well to drug and surgical treatment, researchers are trying to use rapidly developing genetic techniques to develop initial attempts. However, significant obstacles to clinical application of gene therapy still exists, such as insufficient understanding of the nature of cardiovascular disease, limitations of genetic technology, or ethical concerns. This review mainly introduces the types and mechanisms of gene-editing techniques, ethical concerns of gene therapy, the application of gene therapy in atherosclerosis and inheritable cardiovascular diseases, in-stent restenosis, and delivering systems.
format	article
author	Genmao Cao Xuezhen Xuan Ruijing Zhang Jie Hu Honglin Dong
author_facet	Genmao Cao Xuezhen Xuan Ruijing Zhang Jie Hu Honglin Dong
author_sort	Genmao Cao
title	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
title_short	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
title_full	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
title_fullStr	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
title_full_unstemmed	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
title_sort	gene therapy for cardiovascular disease: basic research and clinical prospects
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/23c93cea97e54a12a90c737552338062
work_keys_str_mv	AT genmaocao genetherapyforcardiovasculardiseasebasicresearchandclinicalprospects AT xuezhenxuan genetherapyforcardiovasculardiseasebasicresearchandclinicalprospects AT ruijingzhang genetherapyforcardiovasculardiseasebasicresearchandclinicalprospects AT jiehu genetherapyforcardiovasculardiseasebasicresearchandclinicalprospects AT honglindong genetherapyforcardiovasculardiseasebasicresearchandclinicalprospects
_version_	1718444275356663808

Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects

Ejemplares similares